Introduction/Background Although most cervical cancer cases are caused by persistent high-risk human papilloma virus (HR-HPV) infection, non-human papilloma virus associated cervical cancer (NHPVA CC) is now considered an independent category. The study aimed to provide clinicopathological characteristics of NHPVA CC).

Methodology A retrospective cohort study of cervical cancer cases presented to a single GYN oncology unit between September 2019 and September 2023. Using p16 as a marker for HPV, cases were classified into HPV-associated cervical cancer (HPVA CC) and NHPVA CC. Clinicopathologic and epidemiological criteria were compared between both groups.

Results The total number of patients retrieved in the study was 99; NHPVA CC represented 21.2% of them. The mean age at the presentation of the NHPVA group is 58.57 which is considered older than the HPVA CC group of which the mean age is 53.63 (p=0.069). Regarding the FIGO stage, HPVA CC presents more frequently as early-stage cervical cancer (28.2% of HPVA CC presents at early stages vs. 4.2% of NHPVA CC, p = 0.022). NHPVA CC is more frequently diagnosed as early locally advanced stage cervical cancer (38.1% of NHPVA CC presents as early locally advanced CC vs. 12.8% of HPVA CC, p = 0.021). LN metastases were found more frequently among NHPVA CC than HPVA CC (57.1% of NHPVA CC present with LN metastasis vs. 33.3% of HPVA CC, p=0.046). Histopathological, adenocarcinoma was more presented in NHPVA CC (38.1% of NHPVA CC vs. 12.8% of HPVA CC, p = 0.021), unlike HPVA CC which mainly of the SCC type (82.1% of HPVA CC vs. 57.1% of NHPVA CC, p=0.038).

Conclusion NHPVA CC represents a significant proportion of cervical cancer patients in our community, and it has its clinic-pathological criteria which raises attention that it might have different pathogenesis of cervical cancer development.

Disclosures The authors declare no conflict of interest. This research received no external funding.